| ［1］ |
Fredman G, Serhan CN. Specialized pro⁃resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease［J］. Nat Rev Cardiol, 2024,21（11）:808⁃823. doi: 10.1038/s41569⁃023⁃00984⁃x.
|
| ［2］ |
Wang X, Ma R, Shi R, et al. Sex differences in the association between plasma polyunsaturated fatty acids levels and moderate⁃to⁃severe plaque psoriasis severity: a cross⁃sectional and longitudinal study［J］. J Transl Med, 2023,21（1）:834. doi: 10. 1186/s12967⁃023⁃04726⁃y.
|
| ［3］ |
Merlin J, Park J, Vandekolk TH, et al. Multipathway in vitro pharmacological characterization of specialized proresolving G protein⁃coupled receptors［J］. Mol Pharmacol, 2022,101（4）:246⁃256. doi: 10.1124/molpharm.121.000422.
|
| ［4］ |
Hu F, Qu Z, Chen K, et al. Lipoxin A4 ameliorates imiquimod⁃induced psoriasis⁃like dermatitis via promoting the regression of inflammation［J］. Clin Cosmet Investig Dermatol, 2023,16:2103⁃2111. doi: 10.2147/CCID.S418467.
|
| ［5］ |
Schottelius AJ, Giesen C, Asadullah K, et al. An aspirin⁃triggered lipoxin A4 stable analog displays a unique topical anti⁃inflammatory profile［J］. J Immunol, 2002,169（12）:7063⁃7070. doi: 10.4049/jimmunol.169.12.7063.
|
| ［6］ |
Brown AL. And the germline beat （AML） goes on［J］. Blood, 2022,139（8）:1126⁃1128. doi: 10.1182/blood.2021013771.
|
| ［7］ |
Gao J, Su Y, Wang Z. Lung inflammation resolution by RvD1 and RvD2 in a receptor⁃dependent manner［J］. Pharmaceutics, 2023,15（5）:1527. doi: 10.3390/pharmaceutics15051527.
|
| ［8］ |
Campbell EL, Louis NA, Tomassetti SE, et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution［J］. FASEB J, 2007,21（12）:3162⁃3170. doi: 10.1096/fj.07⁃8473com.
|
| ［9］ |
Liang Z, Yue H, Xu C, et al. Protectin DX relieve hyperoxia⁃induced lung injury by protecting pulmonary endothelial glycocalyx［J］. J Inflamm Res, 2023,16:421⁃431. doi: 10.2147/JIR.S391765.
|
| ［10］ |
Chen O, Donnelly CR, Ji RR. Regulation of pain by neuro⁃immune interactions between macrophages and nociceptor sensory neurons［J］. Curr Opin Neurobiol, 2020,62:17⁃25. doi: 10.1016/j.conb.2019.11.006.
|
| ［11］ |
Belayev L, Hong SH, Menghani H, et al. Docosanoids promote neurogenesis and angiogenesis, blood⁃brain barrier integrity, penumbra protection, and neurobehavioral recovery after experimental ischemic stroke［J］. Mol Neurobiol, 2018,55（8）:7090⁃7106. doi: 10.1007/s12035⁃018⁃1136⁃3.
|
| ［12］ |
Leroy V, Cai J, Filiberto A, et al. Resolution of post⁃lung transplant ischemia⁃reperfusion injury is mediated via resolvin D1⁃Alx/FPR2 and maresin 1⁃LGR6 receptor signaling［J］. The Journal of Heart and Lung Transplantation, 2021,40（4）:s55⁃s56. doi:10.1016/j.healun.2021.01.1876.
|
| ［13］ |
Chiang N, Libreros S, Norris PC, et al. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions［J］. J Clin Invest, 2023,133（2）:e168084. doi: 10.1172/JCI168084.
|
| ［14］ |
Sun S, Wang L, Wang J, et al. Maresin1 prevents sepsis⁃induced acute liver injury by suppressing NF⁃κB/Stat3/MAPK pathways, mitigating inflammation［J］. Heliyon, 2023,9（11）:e21883. doi: 10.1016/j.heliyon.2023.e21883.
|
| ［15］ |
Saito⁃Sasaki N, Sawada Y, Mashima E, et al. Maresin⁃1 suppresses imiquimod⁃induced skin inflammation by regulating IL⁃23 receptor expression［J］. Sci Rep, 2018,8（1）:5522. doi: 10.1038/s41598⁃018⁃23623⁃9.
|
| ［16］ |
Xu J, Duan X, Hu F, et al. Resolvin D1 attenuates imiquimod⁃induced mice psoriasiform dermatitis through MAPKs and NF⁃κB pathways［J］. J Dermatol Sci, 2018,89（2）:127⁃135. doi: 10. 1016/j.jdermsci.2017.10.016.
|
| ［17］ |
Sawada Y, Honda T, Nakamizo S, et al. Resolvin E1 attenuates murine psoriatic dermatitis［J］. Sci Rep, 2018,8（1）:11873. doi: 10.1038/s41598⁃018⁃30373⁃1.
|
| ［18］ |
Park KD, Kim N, Kang J, et al. Protectin D1 reduces imiquimod⁃induced psoriasiform skin inflammation［J］. Int Immunopharmacol, 2021,98:107883. doi: 10.1016/j.intimp.2021.107883.
|
| ［19］ |
Yuan J, Lin F, Chen L, et al. Lipoxin A4 regulates M1/M2 macrophage polarization via FPR2⁃IRF pathway［J］. Inflammopharmacology, 2022,30（2）:487⁃498. doi: 10.1007/s10787⁃022⁃00942⁃y.
|
| ［20］ |
Maderna P, Cottell DC, Toivonen T, et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin⁃derived peptide⁃stimulated phagocytosis［J］. FASEB J, 2010,24（11）:4240⁃4249. doi: 10.1096/fj.10⁃159913.
|
| ［21］ |
Hu F, Liu XX, Wang X, et al. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes associated with the ERK1/2 and NF⁃κB pathways［J］. J Dermatol Sci, 2015,78（3）:181⁃188. doi: 10.1016/j.jdermsci.2015.03.009.
|
| ［22］ |
Kelly AG, Panigrahy D. Targeting angiogenesis via resolution of inflammation［J］. Cold Spring Harb Perspect Med, 2023,13（3）:a041172. doi: 10.1101/cshperspect.a041172.
|
| ［23］ |
Laban A, Atallah R, Eldahshan R, et al. Assessment of retinal vasculature in patients with psoriasis［J］. International Journal of Medical Arts, 2022,4（11）:2767⁃2774. doi:10.21608/ijma.2023. 176787.1560.
|
| ［24］ |
Sun W, Ma J, Zhao H, et al. Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA⁃146a⁃5p in rheumatoid arthritis［J］. Arthritis Res Ther, 2020,22（1）:61. doi: 10.1186/s13075⁃020⁃2133⁃2.
|
| ［25］ |
Rajasagi NK, Reddy PB, Suryawanshi A, et al. Controlling herpes simplex virus⁃induced ocular inflammatory lesions with the lipid⁃derived mediator resolvin E1［J］. J Immunol, 2011,186（3）:1735⁃1746. doi: 10.4049/jimmunol.1003456.
|
| ［26］ |
Sorokin AV, Arnardottir H, Svirydava M, et al. Comparison of the dietary omega⁃3 fatty acids impact on murine psoriasis⁃like skin inflammation and associated lipid dysfunction［J］. J Nutr Biochem, 2023,117:109348. doi: 10.1016/j.jnutbio.2023.109348.
|
| ［27］ |
Morin S, Simard M, Rioux G, et al. Alpha⁃linolenic acid modulates T cell incorporation in a 3D tissue⁃engineered psoriatic skin model［J］. Cells, 2022,11（9）:1513. doi: 10.3390/cells11091513.
|
| ［28］ |
Morin S, Tremblay A, Dumais E, et al. Eicosapentaenoic acid influences the lipid profile of an in vitro psoriatic skin model produced with T cells［J］. Biomolecules, 2023,13（9）:1413. doi: 10.3390/biom13091413.
|
| ［29］ |
Escobar SO, Achenbach R, Iannantuono R, et al. Topical fish oil in psoriasis⁃⁃a controlled and blind study［J］. Clin Exp Dermatol, 1992,17（3）:159⁃162. doi: 10.1111/j.1365⁃2230.1992.tb00194.x.
|
| ［30］ |
Li N, Qin Y, Dai D, et al. Transdermal delivery of therapeutic compounds with nanotechnological approaches in psoriasis［J］. Front Bioeng Biotechnol, 2021,9:804415. doi: 10.3389/fbioe. 2021.804415.
|
| ［31］ |
Furutani K, Chen O, McGinnis A, et al. Novel proresolving lipid mediator mimetic 3⁃oxa⁃PD1n⁃3 docosapentaenoic acid reduces acute and chronic itch by modulating excitatory and inhibitory synaptic transmission and astroglial secretion of lipocalin⁃2 in mice［J］. Pain, 2023,164（6）:1340⁃1354. doi: 10.1097/j.pain.000 0000000002824.
|
| ［32］ |
Song CH, Wang R, Zhao ZK, et al. Leptin modulates the differentiation of keratinocytes via autophagy in psoriasis patients with metabolic syndrome. Int J Dermatol Venerol, 2024, 7（3）:121⁃130. doi: 10.1097/JD9.0000000000000353.
|
| ［33］ |
Martínez⁃Fernández L, Burgos M, Sáinz N, et al. Maresin 1 exerts a tissue⁃specific regulation of adipo⁃hepato⁃myokines in diet⁃induced obese mice and modulates adipokine expression in cultured human adipocytes in basal and inflammatory conditions［J］. Biomolecules, 2023,13（6）:919. doi: 10.3390/biom13060919.
|
| ［34］ |
Salazar J, Pirela D, Nava M, et al. Specialized proresolving lipid mediators: a potential therapeutic target for atherosclerosis［J］. Int J Mol Sci, 2022,23（6）:3133. doi: 10.3390/ijms23063133.
|
| ［35］ |
Yang WS, Wang JL, Wu W, et al. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease［J］. Acta Pharmacol Sin, 2023,44（1）:19⁃31. doi: 10.1038/s41401⁃022⁃00944⁃0.
|
| ［36］ |
Byrne L, Guiry PJ. Advances in the chemistry and biology of specialised pro⁃resolving mediators （SPMs）［J］. Molecules, 2024,29（10）:2233. doi: 10.3390/molecules29102233.
|
| ［37］ |
Rahman M, Akhter S, Ahmad J, et al. Nanomedicine⁃based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy［J］. Expert Opin Drug Deliv, 2015,12（4）:635⁃652. doi: 10.1517/17425247.2015.982088.
|
